ログイン

Unit 4

Unit 4
42問 • 2年前
  • Quinn Karylle Fuentes
  • 通報

    問題一覧

  • 1

    The basic document from where the master formula and batch production records are based.

    Manufacturing monograph.

  • 2

    The document was generated to explain in detail the reason behind a procedure and proper sequence of steps to be done, and how equipment is to be operated for maximum performance.

    Standard operating procedure.

  • 3

    The document provides the basis for accepting the quality of every component used in the manufacture of the product following the specifications and methods.

    Quality control monograph.

  • 4

    The original document used as the key in the manufacture of products

    Master formula record.

  • 5

    Being the prototype, it is kept in a secured documentation room, duplicated or photocopied only whenever a job order is issued.

    Master formula record.

  • 6

    It assures identical reproduction of the product document.

    Master formula record.

  • 7

    A batch reproduction record is an accurate reproduction of the master formula record (T/F)

    True.

  • 8

    After being used as the guide to production actual data of what has been done are recorded therein

    Batch reproduction record.

  • 9

    A specific amount produced in a unit of time or according to a single manufacturing order during the same cycle of manufacture

    Batch.

  • 10

    A batch, a portion of a batch, or a combination of batches.

    Lot.

  • 11

    The term batch number, lot number, or control number means any distinctive combination of marking, letters, or numbers by which the history of the manufacture and control of a batch or lot of a product can be determined. (T/F)

    True.

  • 12

    Control codes should be identified as such on the label

    Batch and lot number.

  • 13

    Differences in the format and content of batch production records from product to product are to be expected.

    Batch and lot numbers.

  • 14

    To satisfy product identity, purity, safety, quality, and strength, products must be subjected to certain specific tests

    Control test.

  • 15

    Individual company monographs and published compendia provide these.

    Control test.

  • 16

    There are minimum attributes common to general categories of products. Where necessary, some of these tests are performed during processing (IPQC) of the product and repeated in the final product.

    Control test.

  • 17

    Determines the material type, assembly, special properties, and integrity

    Packaging test.

  • 18

    Determines the physical and chemical reactions particular for the compound, and gives the gross physical appearance

    Identification test.

  • 19

    Determines the presence of impurities: gross, chemical, and biological.

    Limit test.

  • 20

    Determines the conformance of dosage form when compared to label claim; this may be instrumental, chemical, or biological.

    Assaying.

  • 21

    Tests for properties, functionalities of particular dosage forms.

    Dosage form.

  • 22

    • During processing, the quality of the product at various stages of production is audited by quality control.

    In process control.

  • 23

    An important requirement of GMP is that the packaging and labeling facilities are inspected before use to ensure that all drug products have been removed from previous operations and that packaging and labeling materials not suitable for subsequent operations have also been remove

    Line clearance.

  • 24

    Reconciliation compares the amount of material going into a process with the amount coming out of the process.

    Yield and reconciliation.

  • 25

    Focuses on losses or apparent gains of materials and is usually used for labeling and packaging operations.

    Reconciliation.

  • 26

    focuses on acceptable product outputs and is usually needed for production processes.

    Yield.

  • 27

    95-100%

    Dry products.

  • 28

    95-102.5%

    Liquid.

  • 29

    90-100%

    Capsule.

  • 30

    85-100%

    Herbal capsule.

  • 31

    - Fear of mix-up or sabotage - Possible pilferage by internal staff - Check for unusual wast

    Out of specs.

  • 32

    the contamination of a starting material, intermediate product, or finished product with another starting material or product during manufacture.

    Cross contamination.

  • 33

    Separate building for Penicillin and Non-penicillin

    Cross contamination.

  • 34

    A clean room is an environment where the particulate contamination & bacterial contamination are limited to prescribed levels

    Clean room.

  • 35

    Minimum particle collective efficiency of 99.97 to 99.997% for a 0.3 micron particle

    High efficacy particulate air.

  • 36

    Minimum particle collection efficiency of 99.9997% efficient for particles greater than or equal to 0.12-micron in size

    Ultra low penetration air.

  • 37

    A process in which the HEPA and ULPA filter is challenged by introducing dispersed particulates, in a form or aerosol, and is measured using a probe

    Filter intergrity testing.

  • 38

    • Di-octylphthalate • PAO (Polyalphaolefin)

    Filter integrity testing.

  • 39

    the entire body of air within a confined area moves with uniform velocity and in a single direction with generally parallel airstreams

    Unidirectional.

  • 40

    class 100 and below have unidirectional airflow patterns.

    Unidirectional.

  • 41

    Conventional flow clean rooms (class 1000 & 10000) have nonunidirectional or mixed airflow patterns.

    non-undirectional.

  • 42

    airflow is not unidirectional by having a varying velocity, multiple pass circulation, or nonparallel flow direction

    Non-unidirectional.

  • Cell structure.

    Cell structure.

    Quinn Karylle Fuentes · 28問 · 2年前

    Cell structure.

    Cell structure.

    28問 • 2年前
    Quinn Karylle Fuentes

    Electrolytes and non electrolytes

    Electrolytes and non electrolytes

    Quinn Karylle Fuentes · 29問 · 2年前

    Electrolytes and non electrolytes

    Electrolytes and non electrolytes

    29問 • 2年前
    Quinn Karylle Fuentes

    MW

    MW

    Quinn Karylle Fuentes · 45問 · 2年前

    MW

    MW

    45問 • 2年前
    Quinn Karylle Fuentes

    POST LAB (EXP 4)

    POST LAB (EXP 4)

    Quinn Karylle Fuentes · 38問 · 2年前

    POST LAB (EXP 4)

    POST LAB (EXP 4)

    38問 • 2年前
    Quinn Karylle Fuentes

    Density and specific gravity

    Density and specific gravity

    Quinn Karylle Fuentes · 34問 · 2年前

    Density and specific gravity

    Density and specific gravity

    34問 • 2年前
    Quinn Karylle Fuentes

    FORCES OF ATTRACTION

    FORCES OF ATTRACTION

    Quinn Karylle Fuentes · 18問 · 2年前

    FORCES OF ATTRACTION

    FORCES OF ATTRACTION

    18問 • 2年前
    Quinn Karylle Fuentes

    Microbial growth

    Microbial growth

    Quinn Karylle Fuentes · 63問 · 2年前

    Microbial growth

    Microbial growth

    63問 • 2年前
    Quinn Karylle Fuentes

    Introduction.

    Introduction.

    Quinn Karylle Fuentes · 61問 · 2年前

    Introduction.

    Introduction.

    61問 • 2年前
    Quinn Karylle Fuentes

    Microbial control.

    Microbial control.

    Quinn Karylle Fuentes · 97問 · 2年前

    Microbial control.

    Microbial control.

    97問 • 2年前
    Quinn Karylle Fuentes

    States of matter

    States of matter

    Quinn Karylle Fuentes · 100問 · 2年前

    States of matter

    States of matter

    100問 • 2年前
    Quinn Karylle Fuentes

    Introduction.

    Introduction.

    Quinn Karylle Fuentes · 86問 · 2年前

    Introduction.

    Introduction.

    86問 • 2年前
    Quinn Karylle Fuentes

    Drug development.

    Drug development.

    Quinn Karylle Fuentes · 77問 · 2年前

    Drug development.

    Drug development.

    77問 • 2年前
    Quinn Karylle Fuentes

    CGMP

    CGMP

    Quinn Karylle Fuentes · 9問 · 2年前

    CGMP

    CGMP

    9問 • 2年前
    Quinn Karylle Fuentes

    Pharmaceutical ingredients.

    Pharmaceutical ingredients.

    Quinn Karylle Fuentes · 24問 · 2年前

    Pharmaceutical ingredients.

    Pharmaceutical ingredients.

    24問 • 2年前
    Quinn Karylle Fuentes

    Powdered & granules

    Powdered & granules

    Quinn Karylle Fuentes · 43問 · 2年前

    Powdered & granules

    Powdered & granules

    43問 • 2年前
    Quinn Karylle Fuentes

    Capsule.

    Capsule.

    Quinn Karylle Fuentes · 24問 · 2年前

    Capsule.

    Capsule.

    24問 • 2年前
    Quinn Karylle Fuentes

    Tablets.

    Tablets.

    Quinn Karylle Fuentes · 23問 · 2年前

    Tablets.

    Tablets.

    23問 • 2年前
    Quinn Karylle Fuentes

    Calculatiom of dose

    Calculatiom of dose

    Quinn Karylle Fuentes · 3回閲覧 · 66問 · 2年前

    Calculatiom of dose

    Calculatiom of dose

    3回閲覧 • 66問 • 2年前
    Quinn Karylle Fuentes

    Postlab 5&6

    Postlab 5&6

    Quinn Karylle Fuentes · 29問 · 2年前

    Postlab 5&6

    Postlab 5&6

    29問 • 2年前
    Quinn Karylle Fuentes

    COLLIGATIVE PROPERTIES.

    COLLIGATIVE PROPERTIES.

    Quinn Karylle Fuentes · 33問 · 2年前

    COLLIGATIVE PROPERTIES.

    COLLIGATIVE PROPERTIES.

    33問 • 2年前
    Quinn Karylle Fuentes

    SEMI SOLID

    SEMI SOLID

    Quinn Karylle Fuentes · 69問 · 2年前

    SEMI SOLID

    SEMI SOLID

    69問 • 2年前
    Quinn Karylle Fuentes

    Basic immunology

    Basic immunology

    Quinn Karylle Fuentes · 60問 · 2年前

    Basic immunology

    Basic immunology

    60問 • 2年前
    Quinn Karylle Fuentes

    Basic immunology (2)

    Basic immunology (2)

    Quinn Karylle Fuentes · 62問 · 2年前

    Basic immunology (2)

    Basic immunology (2)

    62問 • 2年前
    Quinn Karylle Fuentes

    Transdermal

    Transdermal

    Quinn Karylle Fuentes · 44問 · 2年前

    Transdermal

    Transdermal

    44問 • 2年前
    Quinn Karylle Fuentes

    Distribution.

    Distribution.

    Quinn Karylle Fuentes · 43問 · 2年前

    Distribution.

    Distribution.

    43問 • 2年前
    Quinn Karylle Fuentes

    Infectious disease.

    Infectious disease.

    Quinn Karylle Fuentes · 65問 · 2年前

    Infectious disease.

    Infectious disease.

    65問 • 2年前
    Quinn Karylle Fuentes

    Infectious diseases (2)

    Infectious diseases (2)

    Quinn Karylle Fuentes · 79問 · 2年前

    Infectious diseases (2)

    Infectious diseases (2)

    79問 • 2年前
    Quinn Karylle Fuentes

    Gram positive ( Bacteriology)

    Gram positive ( Bacteriology)

    Quinn Karylle Fuentes · 35問 · 2年前

    Gram positive ( Bacteriology)

    Gram positive ( Bacteriology)

    35問 • 2年前
    Quinn Karylle Fuentes

    All topic. ( Compressed.)

    All topic. ( Compressed.)

    Quinn Karylle Fuentes · 35問 · 2年前

    All topic. ( Compressed.)

    All topic. ( Compressed.)

    35問 • 2年前
    Quinn Karylle Fuentes

    All topic ( Compressed)

    All topic ( Compressed)

    Quinn Karylle Fuentes · 30問 · 2年前

    All topic ( Compressed)

    All topic ( Compressed)

    30問 • 2年前
    Quinn Karylle Fuentes

    All topics (compressed)

    All topics (compressed)

    Quinn Karylle Fuentes · 13問 · 2年前

    All topics (compressed)

    All topics (compressed)

    13問 • 2年前
    Quinn Karylle Fuentes

    Exercise 6 ; Isotonic solution.

    Exercise 6 ; Isotonic solution.

    Quinn Karylle Fuentes · 28問 · 2年前

    Exercise 6 ; Isotonic solution.

    Exercise 6 ; Isotonic solution.

    28問 • 2年前
    Quinn Karylle Fuentes

    Exercise 5 : Buffers.

    Exercise 5 : Buffers.

    Quinn Karylle Fuentes · 16問 · 2年前

    Exercise 5 : Buffers.

    Exercise 5 : Buffers.

    16問 • 2年前
    Quinn Karylle Fuentes

    Exercise 7 : Factors affecting solubility.

    Exercise 7 : Factors affecting solubility.

    Quinn Karylle Fuentes · 26問 · 2年前

    Exercise 7 : Factors affecting solubility.

    Exercise 7 : Factors affecting solubility.

    26問 • 2年前
    Quinn Karylle Fuentes

    Experiment 8: Disintegration.

    Experiment 8: Disintegration.

    Quinn Karylle Fuentes · 23問 · 2年前

    Experiment 8: Disintegration.

    Experiment 8: Disintegration.

    23問 • 2年前
    Quinn Karylle Fuentes

    Experiment 9 ; Interfacial phenomenon and surface tension.

    Experiment 9 ; Interfacial phenomenon and surface tension.

    Quinn Karylle Fuentes · 35問 · 2年前

    Experiment 9 ; Interfacial phenomenon and surface tension.

    Experiment 9 ; Interfacial phenomenon and surface tension.

    35問 • 2年前
    Quinn Karylle Fuentes

    EXP 9 : Aromatic ammonia spirit.

    EXP 9 : Aromatic ammonia spirit.

    Quinn Karylle Fuentes · 34問 · 2年前

    EXP 9 : Aromatic ammonia spirit.

    EXP 9 : Aromatic ammonia spirit.

    34問 • 2年前
    Quinn Karylle Fuentes

    EXP 10-11 : CAMPHOR WATER AND CINNAMON WATER.

    EXP 10-11 : CAMPHOR WATER AND CINNAMON WATER.

    Quinn Karylle Fuentes · 34問 · 2年前

    EXP 10-11 : CAMPHOR WATER AND CINNAMON WATER.

    EXP 10-11 : CAMPHOR WATER AND CINNAMON WATER.

    34問 • 2年前
    Quinn Karylle Fuentes

    EXP 12: ACACIA MUCILAGE

    EXP 12: ACACIA MUCILAGE

    Quinn Karylle Fuentes · 20問 · 2年前

    EXP 12: ACACIA MUCILAGE

    EXP 12: ACACIA MUCILAGE

    20問 • 2年前
    Quinn Karylle Fuentes

    EXP13&14 : Starch and Barrium sulfate.

    EXP13&14 : Starch and Barrium sulfate.

    Quinn Karylle Fuentes · 33問 · 2年前

    EXP13&14 : Starch and Barrium sulfate.

    EXP13&14 : Starch and Barrium sulfate.

    33問 • 2年前
    Quinn Karylle Fuentes

    EXP 15 : Liquid petroleum emulsion 1.0

    EXP 15 : Liquid petroleum emulsion 1.0

    Quinn Karylle Fuentes · 37問 · 2年前

    EXP 15 : Liquid petroleum emulsion 1.0

    EXP 15 : Liquid petroleum emulsion 1.0

    37問 • 2年前
    Quinn Karylle Fuentes

    EXP 15: Liquid petroleum emulsion 1.1

    EXP 15: Liquid petroleum emulsion 1.1

    Quinn Karylle Fuentes · 23問 · 2年前

    EXP 15: Liquid petroleum emulsion 1.1

    EXP 15: Liquid petroleum emulsion 1.1

    23問 • 2年前
    Quinn Karylle Fuentes

    Enterobacteriaceae

    Enterobacteriaceae

    Quinn Karylle Fuentes · 35問 · 2年前

    Enterobacteriaceae

    Enterobacteriaceae

    35問 • 2年前
    Quinn Karylle Fuentes

    Enterobacteriaceae.

    Enterobacteriaceae.

    Quinn Karylle Fuentes · 28問 · 2年前

    Enterobacteriaceae.

    Enterobacteriaceae.

    28問 • 2年前
    Quinn Karylle Fuentes

    LIQUID DOSAGE FORM 1.0

    LIQUID DOSAGE FORM 1.0

    Quinn Karylle Fuentes · 31問 · 2年前

    LIQUID DOSAGE FORM 1.0

    LIQUID DOSAGE FORM 1.0

    31問 • 2年前
    Quinn Karylle Fuentes

    Liquid dosage form

    Liquid dosage form

    Quinn Karylle Fuentes · 12問 · 2年前

    Liquid dosage form

    Liquid dosage form

    12問 • 2年前
    Quinn Karylle Fuentes

    MICROMERITICS 1.0

    MICROMERITICS 1.0

    Quinn Karylle Fuentes · 44問 · 2年前

    MICROMERITICS 1.0

    MICROMERITICS 1.0

    44問 • 2年前
    Quinn Karylle Fuentes

    EXP 7 : ENDOGENOUS AND EXOGENOUS MICROORGANISMS

    EXP 7 : ENDOGENOUS AND EXOGENOUS MICROORGANISMS

    Quinn Karylle Fuentes · 22問 · 2年前

    EXP 7 : ENDOGENOUS AND EXOGENOUS MICROORGANISMS

    EXP 7 : ENDOGENOUS AND EXOGENOUS MICROORGANISMS

    22問 • 2年前
    Quinn Karylle Fuentes

    EXP 8 : KIRBY-BAUER TECHNIQUE

    EXP 8 : KIRBY-BAUER TECHNIQUE

    Quinn Karylle Fuentes · 40問 · 2年前

    EXP 8 : KIRBY-BAUER TECHNIQUE

    EXP 8 : KIRBY-BAUER TECHNIQUE

    40問 • 2年前
    Quinn Karylle Fuentes

    EXP 9: STAPHYLOCOCCI

    EXP 9: STAPHYLOCOCCI

    Quinn Karylle Fuentes · 29問 · 2年前

    EXP 9: STAPHYLOCOCCI

    EXP 9: STAPHYLOCOCCI

    29問 • 2年前
    Quinn Karylle Fuentes

    Drug incompatibilities.

    Drug incompatibilities.

    Quinn Karylle Fuentes · 41問 · 2年前

    Drug incompatibilities.

    Drug incompatibilities.

    41問 • 2年前
    Quinn Karylle Fuentes

    Drug compatibilities.

    Drug compatibilities.

    Quinn Karylle Fuentes · 41問 · 2年前

    Drug compatibilities.

    Drug compatibilities.

    41問 • 2年前
    Quinn Karylle Fuentes

    BACTERIOLOGY 3

    BACTERIOLOGY 3

    Quinn Karylle Fuentes · 35問 · 2年前

    BACTERIOLOGY 3

    BACTERIOLOGY 3

    35問 • 2年前
    Quinn Karylle Fuentes

    BACTERIOLOGY 3

    BACTERIOLOGY 3

    Quinn Karylle Fuentes · 30問 · 2年前

    BACTERIOLOGY 3

    BACTERIOLOGY 3

    30問 • 2年前
    Quinn Karylle Fuentes

    SUSPENSION.

    SUSPENSION.

    Quinn Karylle Fuentes · 45問 · 2年前

    SUSPENSION.

    SUSPENSION.

    45問 • 2年前
    Quinn Karylle Fuentes

    Colloidal.

    Colloidal.

    Quinn Karylle Fuentes · 40問 · 2年前

    Colloidal.

    Colloidal.

    40問 • 2年前
    Quinn Karylle Fuentes

    BACTERIOLOGY 4 (Rickettsia)

    BACTERIOLOGY 4 (Rickettsia)

    Quinn Karylle Fuentes · 38問 · 2年前

    BACTERIOLOGY 4 (Rickettsia)

    BACTERIOLOGY 4 (Rickettsia)

    38問 • 2年前
    Quinn Karylle Fuentes

    BACTERIOLOGY.

    BACTERIOLOGY.

    Quinn Karylle Fuentes · 44問 · 2年前

    BACTERIOLOGY.

    BACTERIOLOGY.

    44問 • 2年前
    Quinn Karylle Fuentes

    Emulsion.

    Emulsion.

    Quinn Karylle Fuentes · 32問 · 2年前

    Emulsion.

    Emulsion.

    32問 • 2年前
    Quinn Karylle Fuentes

    EMULSION

    EMULSION

    Quinn Karylle Fuentes · 42問 · 2年前

    EMULSION

    EMULSION

    42問 • 2年前
    Quinn Karylle Fuentes

    MEDICAL RELATED PROBLEMS.

    MEDICAL RELATED PROBLEMS.

    Quinn Karylle Fuentes · 36問 · 2年前

    MEDICAL RELATED PROBLEMS.

    MEDICAL RELATED PROBLEMS.

    36問 • 2年前
    Quinn Karylle Fuentes

    MEDICATION RELATED PROBLEMS.

    MEDICATION RELATED PROBLEMS.

    Quinn Karylle Fuentes · 33問 · 2年前

    MEDICATION RELATED PROBLEMS.

    MEDICATION RELATED PROBLEMS.

    33問 • 2年前
    Quinn Karylle Fuentes

    Mycology.

    Mycology.

    Quinn Karylle Fuentes · 30問 · 2年前

    Mycology.

    Mycology.

    30問 • 2年前
    Quinn Karylle Fuentes

    Mycology 2.0

    Mycology 2.0

    Quinn Karylle Fuentes · 34問 · 2年前

    Mycology 2.0

    Mycology 2.0

    34問 • 2年前
    Quinn Karylle Fuentes

    m

    m

    Quinn Karylle Fuentes · 15問 · 2年前

    m

    m

    15問 • 2年前
    Quinn Karylle Fuentes

    ppr

    ppr

    Quinn Karylle Fuentes · 25問 · 2年前

    ppr

    ppr

    25問 • 2年前
    Quinn Karylle Fuentes

    MEDICAL DEVICES.

    MEDICAL DEVICES.

    Quinn Karylle Fuentes · 20問 · 2年前

    MEDICAL DEVICES.

    MEDICAL DEVICES.

    20問 • 2年前
    Quinn Karylle Fuentes

    Pharmacokinetics. (1.0)

    Pharmacokinetics. (1.0)

    Quinn Karylle Fuentes · 86問 · 2年前

    Pharmacokinetics. (1.0)

    Pharmacokinetics. (1.0)

    86問 • 2年前
    Quinn Karylle Fuentes

    Pharmacokinetics (1.1)

    Pharmacokinetics (1.1)

    Quinn Karylle Fuentes · 100問 · 2年前

    Pharmacokinetics (1.1)

    Pharmacokinetics (1.1)

    100問 • 2年前
    Quinn Karylle Fuentes

    Pharmacokinetics (1.2)

    Pharmacokinetics (1.2)

    Quinn Karylle Fuentes · 19問 · 2年前

    Pharmacokinetics (1.2)

    Pharmacokinetics (1.2)

    19問 • 2年前
    Quinn Karylle Fuentes

    Introduction.

    Introduction.

    Quinn Karylle Fuentes · 17問 · 2年前

    Introduction.

    Introduction.

    17問 • 2年前
    Quinn Karylle Fuentes

    Introduction of biochemistry

    Introduction of biochemistry

    Quinn Karylle Fuentes · 76問 · 2年前

    Introduction of biochemistry

    Introduction of biochemistry

    76問 • 2年前
    Quinn Karylle Fuentes

    Intro medicanal chemistry.

    Intro medicanal chemistry.

    Quinn Karylle Fuentes · 56問 · 2年前

    Intro medicanal chemistry.

    Intro medicanal chemistry.

    56問 • 2年前
    Quinn Karylle Fuentes

    Carbohydrates

    Carbohydrates

    Quinn Karylle Fuentes · 75問 · 2年前

    Carbohydrates

    Carbohydrates

    75問 • 2年前
    Quinn Karylle Fuentes

    Carbohydrates 1.1

    Carbohydrates 1.1

    Quinn Karylle Fuentes · 31問 · 2年前

    Carbohydrates 1.1

    Carbohydrates 1.1

    31問 • 2年前
    Quinn Karylle Fuentes

    Detect and quality variation.

    Detect and quality variation.

    Quinn Karylle Fuentes · 56問 · 2年前

    Detect and quality variation.

    Detect and quality variation.

    56問 • 2年前
    Quinn Karylle Fuentes

    INTRODUCTION

    INTRODUCTION

    Quinn Karylle Fuentes · 98問 · 2年前

    INTRODUCTION

    INTRODUCTION

    98問 • 2年前
    Quinn Karylle Fuentes

    lab (1-2)

    lab (1-2)

    Quinn Karylle Fuentes · 15問 · 2年前

    lab (1-2)

    lab (1-2)

    15問 • 2年前
    Quinn Karylle Fuentes

    lab 1-2

    lab 1-2

    Quinn Karylle Fuentes · 14問 · 2年前

    lab 1-2

    lab 1-2

    14問 • 2年前
    Quinn Karylle Fuentes

    Pharmaceutical chemistry.

    Pharmaceutical chemistry.

    Quinn Karylle Fuentes · 45問 · 2年前

    Pharmaceutical chemistry.

    Pharmaceutical chemistry.

    45問 • 2年前
    Quinn Karylle Fuentes

    Pharmaceutical chemistry 1.1

    Pharmaceutical chemistry 1.1

    Quinn Karylle Fuentes · 35問 · 2年前

    Pharmaceutical chemistry 1.1

    Pharmaceutical chemistry 1.1

    35問 • 2年前
    Quinn Karylle Fuentes

    Unit 3.

    Unit 3.

    Quinn Karylle Fuentes · 39問 · 2年前

    Unit 3.

    Unit 3.

    39問 • 2年前
    Quinn Karylle Fuentes

    Histamin and kinins

    Histamin and kinins

    Quinn Karylle Fuentes · 70問 · 2年前

    Histamin and kinins

    Histamin and kinins

    70問 • 2年前
    Quinn Karylle Fuentes

    PUD.

    PUD.

    Quinn Karylle Fuentes · 45問 · 2年前

    PUD.

    PUD.

    45問 • 2年前
    Quinn Karylle Fuentes

    ..

    ..

    Quinn Karylle Fuentes · 61問 · 2年前

    ..

    ..

    61問 • 2年前
    Quinn Karylle Fuentes

    Lipids.

    Lipids.

    Quinn Karylle Fuentes · 67問 · 2年前

    Lipids.

    Lipids.

    67問 • 2年前
    Quinn Karylle Fuentes

    lipids.

    lipids.

    Quinn Karylle Fuentes · 71問 · 2年前

    lipids.

    lipids.

    71問 • 2年前
    Quinn Karylle Fuentes

    LAB ✨

    LAB ✨

    Quinn Karylle Fuentes · 93問 · 2年前

    LAB ✨

    LAB ✨

    93問 • 2年前
    Quinn Karylle Fuentes

    Drug discovery.

    Drug discovery.

    Quinn Karylle Fuentes · 87問 · 2年前

    Drug discovery.

    Drug discovery.

    87問 • 2年前
    Quinn Karylle Fuentes

    disease of lipids.

    disease of lipids.

    Quinn Karylle Fuentes · 13問 · 2年前

    disease of lipids.

    disease of lipids.

    13問 • 2年前
    Quinn Karylle Fuentes

    Intro (identify structure)

    Intro (identify structure)

    Quinn Karylle Fuentes · 57問 · 2年前

    Intro (identify structure)

    Intro (identify structure)

    57問 • 2年前
    Quinn Karylle Fuentes

    Carbohydrates

    Carbohydrates

    Quinn Karylle Fuentes · 98問 · 2年前

    Carbohydrates

    Carbohydrates

    98問 • 2年前
    Quinn Karylle Fuentes

    Dynamic.

    Dynamic.

    Quinn Karylle Fuentes · 96問 · 2年前

    Dynamic.

    Dynamic.

    96問 • 2年前
    Quinn Karylle Fuentes

    Unit 1

    Unit 1

    Quinn Karylle Fuentes · 32問 · 2年前

    Unit 1

    Unit 1

    32問 • 2年前
    Quinn Karylle Fuentes

    問題一覧

  • 1

    The basic document from where the master formula and batch production records are based.

    Manufacturing monograph.

  • 2

    The document was generated to explain in detail the reason behind a procedure and proper sequence of steps to be done, and how equipment is to be operated for maximum performance.

    Standard operating procedure.

  • 3

    The document provides the basis for accepting the quality of every component used in the manufacture of the product following the specifications and methods.

    Quality control monograph.

  • 4

    The original document used as the key in the manufacture of products

    Master formula record.

  • 5

    Being the prototype, it is kept in a secured documentation room, duplicated or photocopied only whenever a job order is issued.

    Master formula record.

  • 6

    It assures identical reproduction of the product document.

    Master formula record.

  • 7

    A batch reproduction record is an accurate reproduction of the master formula record (T/F)

    True.

  • 8

    After being used as the guide to production actual data of what has been done are recorded therein

    Batch reproduction record.

  • 9

    A specific amount produced in a unit of time or according to a single manufacturing order during the same cycle of manufacture

    Batch.

  • 10

    A batch, a portion of a batch, or a combination of batches.

    Lot.

  • 11

    The term batch number, lot number, or control number means any distinctive combination of marking, letters, or numbers by which the history of the manufacture and control of a batch or lot of a product can be determined. (T/F)

    True.

  • 12

    Control codes should be identified as such on the label

    Batch and lot number.

  • 13

    Differences in the format and content of batch production records from product to product are to be expected.

    Batch and lot numbers.

  • 14

    To satisfy product identity, purity, safety, quality, and strength, products must be subjected to certain specific tests

    Control test.

  • 15

    Individual company monographs and published compendia provide these.

    Control test.

  • 16

    There are minimum attributes common to general categories of products. Where necessary, some of these tests are performed during processing (IPQC) of the product and repeated in the final product.

    Control test.

  • 17

    Determines the material type, assembly, special properties, and integrity

    Packaging test.

  • 18

    Determines the physical and chemical reactions particular for the compound, and gives the gross physical appearance

    Identification test.

  • 19

    Determines the presence of impurities: gross, chemical, and biological.

    Limit test.

  • 20

    Determines the conformance of dosage form when compared to label claim; this may be instrumental, chemical, or biological.

    Assaying.

  • 21

    Tests for properties, functionalities of particular dosage forms.

    Dosage form.

  • 22

    • During processing, the quality of the product at various stages of production is audited by quality control.

    In process control.

  • 23

    An important requirement of GMP is that the packaging and labeling facilities are inspected before use to ensure that all drug products have been removed from previous operations and that packaging and labeling materials not suitable for subsequent operations have also been remove

    Line clearance.

  • 24

    Reconciliation compares the amount of material going into a process with the amount coming out of the process.

    Yield and reconciliation.

  • 25

    Focuses on losses or apparent gains of materials and is usually used for labeling and packaging operations.

    Reconciliation.

  • 26

    focuses on acceptable product outputs and is usually needed for production processes.

    Yield.

  • 27

    95-100%

    Dry products.

  • 28

    95-102.5%

    Liquid.

  • 29

    90-100%

    Capsule.

  • 30

    85-100%

    Herbal capsule.

  • 31

    - Fear of mix-up or sabotage - Possible pilferage by internal staff - Check for unusual wast

    Out of specs.

  • 32

    the contamination of a starting material, intermediate product, or finished product with another starting material or product during manufacture.

    Cross contamination.

  • 33

    Separate building for Penicillin and Non-penicillin

    Cross contamination.

  • 34

    A clean room is an environment where the particulate contamination & bacterial contamination are limited to prescribed levels

    Clean room.

  • 35

    Minimum particle collective efficiency of 99.97 to 99.997% for a 0.3 micron particle

    High efficacy particulate air.

  • 36

    Minimum particle collection efficiency of 99.9997% efficient for particles greater than or equal to 0.12-micron in size

    Ultra low penetration air.

  • 37

    A process in which the HEPA and ULPA filter is challenged by introducing dispersed particulates, in a form or aerosol, and is measured using a probe

    Filter intergrity testing.

  • 38

    • Di-octylphthalate • PAO (Polyalphaolefin)

    Filter integrity testing.

  • 39

    the entire body of air within a confined area moves with uniform velocity and in a single direction with generally parallel airstreams

    Unidirectional.

  • 40

    class 100 and below have unidirectional airflow patterns.

    Unidirectional.

  • 41

    Conventional flow clean rooms (class 1000 & 10000) have nonunidirectional or mixed airflow patterns.

    non-undirectional.

  • 42

    airflow is not unidirectional by having a varying velocity, multiple pass circulation, or nonparallel flow direction

    Non-unidirectional.